CN1063449C - 一种胆甾醇化合物及其提取方法 - Google Patents
一种胆甾醇化合物及其提取方法 Download PDFInfo
- Publication number
- CN1063449C CN1063449C CN96122199A CN96122199A CN1063449C CN 1063449 C CN1063449 C CN 1063449C CN 96122199 A CN96122199 A CN 96122199A CN 96122199 A CN96122199 A CN 96122199A CN 1063449 C CN1063449 C CN 1063449C
- Authority
- CN
- China
- Prior art keywords
- compound
- ethyl acetate
- extract
- sponge
- stelletta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims description 4
- -1 Cholestrin compound Chemical class 0.000 title abstract description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 22
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000000126 substance Substances 0.000 claims abstract description 9
- 238000000605 extraction Methods 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 5
- 241001349863 Stelletta Species 0.000 claims abstract description 5
- 239000013078 crystal Substances 0.000 claims abstract description 4
- 238000001953 recrystallisation Methods 0.000 claims abstract description 4
- 238000010898 silica gel chromatography Methods 0.000 claims abstract description 3
- 235000014347 soups Nutrition 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 4
- 241000243142 Porifera Species 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 150000001841 cholesterols Chemical class 0.000 claims description 3
- 238000010828 elution Methods 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 2
- 238000002425 crystallisation Methods 0.000 claims description 2
- 230000008025 crystallization Effects 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 claims description 2
- NIQQIJXGUZVEBB-UHFFFAOYSA-N methanol;propan-2-one Chemical compound OC.CC(C)=O NIQQIJXGUZVEBB-UHFFFAOYSA-N 0.000 claims description 2
- 239000012046 mixed solvent Substances 0.000 claims description 2
- 239000003208 petroleum Substances 0.000 claims description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract description 3
- 208000007536 Thrombosis Diseases 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 239000002904 solvent Substances 0.000 abstract 3
- HVYWMOMLDIMFJA-UHFFFAOYSA-N 3-cholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 HVYWMOMLDIMFJA-UHFFFAOYSA-N 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 1
- 238000002386 leaching Methods 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N methyl alcohol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
Landscapes
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一种从中国南海海绵Stelletta sp.中提取分离的新胆甾醇化合物。
本发明所述的化合物的化学名为:25(29)-亚甲基-26-甲基-26-乙基胆甾醇,被命名为Stellesterol,其化学结构式如下;
该化合物是以工业乙醇从中国南海海绵Stelletta SP.中提取、浓缩,并以乙酸乙酯等溶剂萃取,经硅胶柱层析和适当的溶剂淋洗,再用合适的溶剂重结晶而得无色针状晶体。该化合物不但具有新的化学结构,而且具有较强的抑制血小板凝聚,抗血栓,活血化瘀作用。因此,具有良好的应用前景。
Description
本发明涉及一种从中国南海Stelletta sp.中分离提取的新胆甾醇化合物。
海绵是一种低等的多细胞动物,种类繁多,分布极广。以海产为主。自七十年代以来,人们已从海绵中发现了许多结构独特的甾体、萜类、生物碱和大环内酯等化合物。其中许多具有抗肿瘤、抗心血管病、抗菌和抗病毒等生理活性,不少化合物具有潜在的临床应用价值,有些已发展成为治疗人类重大疾病的特效药物。
该化合物的化学名称为:25(29)-亚甲基-26甲基-26-乙基胆甾醇,被命名为:Stellesterol,其物理常数如下:
无色结晶体,m.p.:128~130℃;[α]D:-24.7°(C=0.018,丙酮);v max(cm-1):3434,2934,2867,1641,1461,1379,1061,890,830,804;δ1H(CDCl3)ppm:5.35(1H,d,J=2.8Hz,6-H),4.70(2H,s,29-H),3.53(1H,m,3α-H),1.01(3H,S,19-CH3),1.00(3H,d,J=8.2Hz,30-CH3),0.95(3H,d,J=6.5Hz,21-CH3),0.84(3H,t,J=7.4Hz,28-CH3),0.69(3H,s,18-CH3);δ13C(CDCl3)ppm:155.26(s,c25),140.75(s,c5),121.65(d,c6),107(t,c29),71.75(d,c3),56.75(d,c14),56.01(d,c17),50.13(d,c9),42.34(t,c4),42.27(s,c13),41.68(d,c26),39.78(t,c12),37.25(t,c1),36.49(s,c10),35.75(d,c20),34.63(t,c22),33.94(t,c23),31.89(t,c7),31.89(d,c8),31.62(t,c2),30.39(t,c24),28.26(t,c27),28.16(t,c16),24.27(t,c15),21.07(t,c11),19.79(q,c19),19.36(q,c30),18.72(q,c21),11.93(q,c28),11.84(q,c18);m/z:426(M+),398,328,314,300,281,271,255,229,213,145,69(100%);HRMS:426.3875(实验值),426.3861(计算值)。
该化合物的提取分离方法如下:晒干的海绵Stelletta sp.经切碎后用乙醇抽提,将抽提物浓缩至浆状物,然后将其分散在适当的水中,再以石油醚、乙酸乙酯和正丁醇依次进行萃取,将所获得的乙酸乙酯可溶物经硅胶柱层析,以石油醚-乙酸乙酯梯度淋洗,获得极性较小的固体物,将此固体物经丙酮-甲醇混合溶剂进行重结晶,得到无色针状晶体。
该化合物的生理活性试验结果表明,具有较强的抑制血小板凝聚,抗血栓作用,在0.2mg/ml浓度下,其抑制率为55%。
本发明所述的新化合物,不但具有新的化学结构,而且具有较强的抑制血小板凝聚,抗血栓,活血化淤作用,因此,本发明所涉及的新化合物具有十分重要的理论价值和应用价值。
实施例:
中国南海海绵Stelletta sp.,晒干(2.7Kg),切碎后用95%工业酒精(5Kg)于室温下抽提三次,合并抽提物并减压浓缩至浆状物,将此浆状物均匀分散于500ml蒸馏水中,以乙酸乙酯(500ml×3)萃取,将萃取物减压浓缩得棕色浆状物64g。
Claims (2)
25(29)-methylene-26-methyl-26-ethylcholesterol英文名称(俗):Stellesterol
物理常数:无色结晶体,m.p.:128~130℃;[α]D:-24.7°(C=0.018,丙酮);ⅴmax(cm-1):3434,2934,2867,1641,1461,1379,1061,890,830,804;δ1H(CDCl3)ppm:5.35(1H,d,J=2.8Hz,6-H),4.70(2H,s,29-H),3.53(1H,m,3α-H),1.01(3H,S,19-CH3),1.00(3H,d,J=8.2Hz,30-CH3),0.95(3H,d,J=6.5Hz,21-CH3),0.84(3H,t,J=7.4Hz,28-CH3),0.69(3H,s,18-CH3);δ13C(CDCl3)ppm:155.26(s,c25),140.75(s,c5),121.65(d,c6),107(t,c29),71.75(d,c3),56.75(d,c14),56.01(d,c17),50.13(d,c9),42.34(t,c4),42.27(s,c13),41.68(d,c26),39.78(t,c12),37.25(t,c1),36.49(s,c10),35.75(d,c20),34.63(t,c22),33.94(t,c23),31.89(t,c7),31.89(d,c8),31.62(t,c2),30.39(t,c24),28.26(t,c27),28.16(t,c16),24.27(t,c15),21.07(t,c11),19.79(q,c19),19.36(q,c30),18.72(q,c21),11.93(q,c28),11.84(q,c18);m/z:426(M+),398,328,314,300,281,271,255,229,213,145,69(100%);HRMS:426.3875(实验值),426.3861(计算值)。
2.一种用于在海绵中分离提取权利要求1中所述化合物的方法,其特征在于将晒干的海绵切碎后用乙醇抽提,将抽提物浓缩至浆状物,然后将其分散在适量的水中,再以石油醚、乙酸乙酯和正丁醇依次进行萃取,将所得的乙酸乙酯可溶物经硅胶柱层析,以石油醚-乙酸乙酯梯度淋洗,获得极性较小的固体物,将此固体物经丙酮-甲醇混合溶剂进行重结晶,得无色针状晶体,即权利要求1中所述的化合物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN96122199A CN1063449C (zh) | 1996-12-27 | 1996-12-27 | 一种胆甾醇化合物及其提取方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN96122199A CN1063449C (zh) | 1996-12-27 | 1996-12-27 | 一种胆甾醇化合物及其提取方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1160056A CN1160056A (zh) | 1997-09-24 |
CN1063449C true CN1063449C (zh) | 2001-03-21 |
Family
ID=5127161
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN96122199A Expired - Fee Related CN1063449C (zh) | 1996-12-27 | 1996-12-27 | 一种胆甾醇化合物及其提取方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1063449C (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100358516C (zh) * | 2004-12-07 | 2008-01-02 | 中国科学院大连化学物理研究所 | 一种多皱软磺酸在抗hiv-1病毒的药物中的应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN87106177A (zh) * | 1986-09-04 | 1988-04-20 | 美克德株式会社 | 唾液酸糖基胆甾醇,它们的制备方法及含有它们的治疗神经病的药物 |
CN1081682A (zh) * | 1992-03-27 | 1994-02-09 | 伊莱利利公司 | 甾类衍生物 |
CN1084856A (zh) * | 1992-07-02 | 1994-04-06 | 纽约大学 | 氨基胆固醇的制法 |
-
1996
- 1996-12-27 CN CN96122199A patent/CN1063449C/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN87106177A (zh) * | 1986-09-04 | 1988-04-20 | 美克德株式会社 | 唾液酸糖基胆甾醇,它们的制备方法及含有它们的治疗神经病的药物 |
CN1081682A (zh) * | 1992-03-27 | 1994-02-09 | 伊莱利利公司 | 甾类衍生物 |
CN1084856A (zh) * | 1992-07-02 | 1994-04-06 | 纽约大学 | 氨基胆固醇的制法 |
Also Published As
Publication number | Publication date |
---|---|
CN1160056A (zh) | 1997-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103665079B (zh) | 一种茯苓酸单体的分离纯化方法 | |
CN1063449C (zh) | 一种胆甾醇化合物及其提取方法 | |
CN103396421B (zh) | 一种银杏内酯c的分离纯化方法 | |
Weng et al. | Two new pentacyclic triterpenoids from Centella asiatica | |
CN101407536B (zh) | 一种溶剂结晶法制备高纯度积雪草苷的工艺 | |
JPH07324037A (ja) | 月桃から血小板凝集抑制物質の製造法 | |
CN102920727B (zh) | 制备富含牡荆素鼠李糖苷和牡荆素葡萄糖苷提取物的方法 | |
CN114634537A (zh) | 金叶子二萜的制备方法及其应用 | |
US11147848B2 (en) | Extracts and isolated compounds from Cakile arabica for treatment of ulcer | |
CN107011140A (zh) | 一种单萜类化合物及其制备方法与应用 | |
CN103113439A (zh) | 从对叶大戟中制备山奈酚-3-O-β-D-葡萄糖醛酸苷的方法 | |
CN1161370C (zh) | 拟人参皂苷f11的制备方法 | |
CN1167704C (zh) | 银杏内酯的生产工艺 | |
CN105061458B (zh) | 一种无毒、高纯银杏总内酯及其单体的制备方法 | |
CN102372759A (zh) | 一种泽泻醇a的提纯方法 | |
CN1110501C (zh) | 一种从海绵中提取的胆甾醇醋酸酯及制法 | |
JP2001316398A (ja) | 抗アレルギー剤 | |
CN114605247B (zh) | 一种二萜类衍生物及其制备方法与镇痛药物、小脆柄菇发酵得物及其乙酸乙酯萃取液 | |
CN117586217B (zh) | 一种基于国产毛喉鞘蕊花的佛司可林制备方法 | |
JP2792010B2 (ja) | フタリド誘導体及びこれを有効成分とする子宮頚癌細胞の殺細胞剤 | |
JPH0386824A (ja) | ジテルペン系化合物及びこれを有効成分とする抗炎症剤 | |
Bernstein et al. | 16-Hyroxylated Steroids. XIII. 9α-Fluoro-11β, 16α-dihydroxy-4-androstene-3, 17-dione | |
CN112552150B (zh) | 一种基于配位效应制备细辛醚单体的方法 | |
CN109912398B (zh) | 一种从东北岩高兰中提取、分离纯化5种查耳酮的方法 | |
JP2757342B2 (ja) | イソインドリノン誘導体及びこれを有効成分とする子宮頚癌細胞の殺細胞剤並びにその製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |